Most pages on this subject give you a long list of things to stop taking. The evidence supports a much shorter one.
The useful distinction is between supplements that have shown a real interaction in people receiving chemotherapy, and supplements that look concerning in a laboratory but have not caused problems in actual patients. Those are very different categories, and lumping them together leads people to give up things that were helping them for no reason.
The short list: real evidence in people
St. John’s wort. This is the clearest one. It induces the CYP3A4 enzyme system and the P-glycoprotein transporter, which reduces blood levels of drugs that depend on those pathways. Documented interactions include the chemotherapy agents irinotecan and imatinib, and the effect is strong enough that concurrent use is treated as contraindicated rather than cautioned. Less drug reaching the cancer is the concern here, not toxicity.
Vitamin B12 and iron, when self-supplemented. In a prospective study within a randomized trial of 1,134 breast cancer patients (SWOG S0221), vitamin B12 taken both before and during chemotherapy was significantly associated with poorer disease-free and overall survival, and iron taken during chemotherapy was significantly associated with recurrence.
That finding needs an important qualifier. The study looked at people supplementing on their own. It is a different situation from repletion your oncology team prescribed because your bloodwork showed a deficiency — that decision was made with your numbers in hand. Do not stop a prescribed supplement based on a web page.
High-dose antioxidants — unresolved rather than settled. In the same study, antioxidant supplements (vitamins A, C and E, carotenoids, coenzyme Q10) taken both before and during treatment showed indications of increased recurrence risk, but that finding did not reach statistical significance and the authors described it cautiously. The mechanistic worry is that some chemotherapy protocols work partly through oxidative damage, and high-dose antioxidants may work against them.
This concerns oral supplementation. Intravenous vitamin C at pharmacologic doses behaves differently — at those concentrations ascorbate acts as a pro-oxidant rather than an antioxidant, which is a separate question covered on our high-dose vitamin C page.
Anything affecting bleeding or platelets deserves more attention during periods when platelet counts are already suppressed.
The list that is shorter than you would expect
Several popular botanicals show CYP3A4 effects in laboratory testing, which is why they appear on nearly every “avoid” list online. When they were actually studied in patients, the picture changed.
A review of herb-drug interaction data in cancer patients examined garlic, milk thistle and Panax ginseng alongside St. John’s wort. Garlic showed no CYP3A4 effect in vitro and no effect on the pharmacokinetics of midazolam or docetaxel in clinical studies. Milk thistle and Panax ginseng showed CYP3A4 inhibition in vitro, but in clinical studies neither produced significant interactions with midazolam, irinotecan, docetaxel or imatinib. The likely explanations are poor absorption and bioavailability — what happens in a dish does not always happen in a person.
The authors’ conclusion is worth stating plainly: in vitro data are a useful first signal, but clinical studies are required to confirm a real interaction. St. John’s wort is the one that carried through to patients.
Multivitamins came out clean
In SWOG S0221, multivitamin use showed no association with survival outcomes, and the authors specifically excepted multivitamins when recommending caution about supplements during chemotherapy. For the single most commonly taken product, that is a reassuring result from a well-designed study.
What about everything else
Most supplements have simply not been studied alongside chemotherapy. Major cancer centers say so directly. That is a gap in the research rather than a finding of harm, and it means nobody can hand you a blanket guarantee in either direction.
It also means the alarming framing you encounter online — that supplements are broadly dangerous during treatment — is not what the evidence supports.
Timing usually matters more than stopping
Several of these concerns apply during active infusion windows and not otherwise. The practical answer is often “pause this one during treatment weeks and resume afterward” rather than “stop taking it.” For people whose supplements are genuinely helping with energy, sleep or digestion, that distinction matters.
The step that matters most
Tell your oncology team what you are taking. Your oncology pharmacist is frequently the single most useful person to ask about a specific product, and they can check your actual protocol rather than a general list.
If you are not sure how to raise it, see talking to your oncologist about supplements. For the broader picture, see supplements during chemotherapy.
References
Ambrosone CB, Zirpoli GR, Hutson AD, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2019;38(8):804-814. doi:10.1200/JCO.19.01203
Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004;27(11):773-797. doi:10.2165/00002018-200427110-00003
Goey AKL, Mooiman KD, Beijnen JH, Schellens JHM, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev. 2013;39(7):773-783. doi:10.1016/j.ctrv.2012.12.008
If you are in treatment or recovering from it and want your supplements reviewed against your specific protocol, that is what our supportive care consultation covers. Start with a free 15-minute call.
Alvin Philipose, DC, ICCP
This page is for general educational purposes and does not constitute medical advice, diagnosis, or treatment recommendation. Do not start, stop, or change any supplement during cancer treatment without consulting your treating physician.